TrialSignal
Clinical trial intelligence report
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01750086
Status
COMPLETED
Phase
PHASE4
Sponsor
Massachusetts General Hospital
Executive brief
Investment-Ready Snapshot
The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01750086
Indication
Postmenopausal Osteoporosis
Modality
small molecule
Target
Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
Intervention
Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.